Jared M Campbell1, Matthew D Stephenson, Barbora de Courten, Ian Chapman, Susan M Bellman, Edoardo Aromataris. 1. 1Joanna Briggs Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia 2Monash Centre for Health, Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 3Discipline of Medicine, National Health and Medical Research Council of Australia (NHMRC) Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.
Abstract
REVIEW QUESTION/ OBJECTIVE: The objective of the review is to assess the effect of metformin on the risk, progression and severity of Alzheimer's disease and other forms of dementia, as well as any measures of cognitive performance or impairment.
REVIEW QUESTION/ OBJECTIVE: The objective of the review is to assess the effect of metformin on the risk, progression and severity of Alzheimer's disease and other forms of dementia, as well as any measures of cognitive performance or impairment.
Authors: Jared M Campbell; Matthew D Stephenson; Barbora de Courten; Ian Chapman; Susan M Bellman; Edoardo Aromataris Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472